Skip to main content
. Author manuscript; available in PMC: 2018 Apr 15.
Published in final edited form as: Clin Cancer Res. 2017 Jul 21;23(20):6128–6137. doi: 10.1158/1078-0432.CCR-17-0311

Figure 1.

Figure 1

A. 89Zr-lumretuzumab PET scan with 100 mg unlabeled lumretuzumab 4 days post injection with representative whole body tracer distribution and tracer uptake in multiple brain metastases (black arrows), one lung metastasis behind the liver (white arrow) and the primary tumor (Cancer of the ampulla of Vater, blue arrow). B. 89Zr-lumretuzumab organ biodistribution 4 days post injection for different doses of unlabeled lumretuzumab; 10 mg unlabeled lumretuzumab in white bars (n = 2), 50 mg unlabeled lumretuzumab in grey bars (n = 2), 100 mg unlabeled lumretuzumab in black bars (n = 16).